Yesterday, the SVP, Manuf & Sup Chn of Boston Scientific Corp (BSX), John Bradley Sorenson, sold shares of BSX for $256.7K.
Following John Bradley Sorenson’s last BSX Sell transaction on August 04, 2017, the stock climbed by 14.6%.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $2.63 billion and quarterly net profit of $154 million. In comparison, last year the company earned revenue of $2.49 billion and had a net profit of $555 million. The company has a one-year high of $43.66 and a one-year low of $31.56. BSX’s market cap is $57.71B and the company has a P/E ratio of 41.85.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy BSX with a $50 price target.
The insider sentiment on Boston Scientific Corp has been negative according to 160 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
